Sun Pharma's Dadra facility receives OAI inspection status from the USFDA; stock slips

As of 9:44 a.m., shares of Sun Pharma traded over 1.82 per cent or Rs 29.2, lower at Rs 1574.8 apiece on BSE. The market capitalisation of the company at around the same time stood at Rs 3,77,910.02 crore.

Representative image. Source: Reuters

Sun Pharma shares lost over 2 per cent in Friday's morning deals after the company's Dadra facility received Official Action Indicated (OAI) inspection status from the US Food and Drugs Administration (USFDA).

As of 9:44 a.m., shares of Sun Pharma traded over 1.82 per cent or Rs 29.2, lower at Rs 1,574.8 apiece on BSE. The market capitalisation of the company at around the same time stood at Rs 3,77,910.02 crore.

The pharmaceutical company on Thursday announced that its Dadra facility was inspected from December 4, 2023, to December 15, 2023, and the USFDA has subsequently determined the inspection classification status of this facility as Official Action Indicated (OAI).

"USFDA conducted an inspection at the company’s Dadra facility from December 4, 2023, to December 15, 2023. US FDA has subsequently determined that the inspection classification status of this facility as Official Action Indicated (OAI). We will work with the regulator to achieve fully compliant status," the filing read.

Sun Pharma Q3 performance

Sun Pharmaceutical Industries Ltd reported a 16.52 per cent rise in its consolidated net profit to Rs 2,523.8 crore in the third quarter that ended December 31, 2023. The company had posted a consolidated net profit of Rs 2,166 crore in the year-ago period, Sun Pharmaceutical Industries said in a statement.

Consolidated total revenue from operations during the quarter under review stood at Rs 12,380.7 crore as compared to Rs 11,240.97 crore in the corresponding period a year ago, it added.

Total expenses were higher at Rs 9,560.74 crore as against Rs 8,943.38 crore in the same quarter of FY23.

The company is yet to announce its Q4 result date.

Sun Pharma share price: Past performance

In a year, Sun Pharma shares have gained over 55 per cent, against Nifty50's rise of over 27 per cent.

Catch the latest stock market updates here. For all other news related to business, politics, tech and auto, visit Zeebiz.com.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

Sun Pharma's Dadra facility receives OAI inspection status from the USFDA; stock slips

As of 9:44 a.m., shares of Sun Pharma traded over 1.82 per cent or Rs 29.2, lower at Rs 1574.8 apiece on BSE. The market capitalisation of the company at around the same time stood at Rs 3,77,910.02 crore.

Sun Pharma Q3 performance

Sun Pharma share price: Past performance

RECOMMENDED STORIES

Power of Compounding: How long it will take to build Rs 5 crore corpus with Rs 5,000, Rs 10,000 and Rs 15,000 monthly investments?

SCSS vs FD: Which guaranteed return scheme will give you more quarterly income on Rs 20,00,000 investment?

Small SIP, Big Impact: Rs 1,111 monthly SIP for 40 years, Rs 11,111 for 20 years or Rs 22,222 for 10 years, which do you think works best?

SBI 444-day FD vs PNB 400-day FD: Here's what general and senior citizens will get in maturity on Rs 3.5 lakh and 7 lakh investments in special FDs?

Looking for short term investment ideas? Analysts suggest buying these 2 stocks for potential gain; check targets

PPF Calculations: How to get Rs 72,000 a month tax-free income from Public Provident Fund?

Rs 3,500 Monthly SIP for 35 years vs Rs 35,000 Monthly SIP for 16 Years: Which can give you higher corpus in long term? See calculations

Power of Compounding: How soon will monthly SIP of Rs 11,000 reach Rs 8 crore corpus target?